HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 75.3%

Neg 0% Neu 0% Pos 75.3%

HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $40 to $42.